Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115850 | 0.85 | HPGD (1.00) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL4886815 | 0.77 | HPGD (0.78) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL4891081 | 0.74 | HPGD (0.72) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL2926521 | 0.72 | ALDH1A1 (0.69) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL19726938 | 0.72 | HPGD (0.73) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL21630176 | 0.71 | HPGD (0.71) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL5116644 | 0.71 | HPGD (0.71) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL29410065 | 0.70 | ALDH1A1 (0.74) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL11479230 | 0.70 | HPGD (0.69) | HPGDALDH1A1L3MBTL1POLBHSD17B10 | |
| SCHEMBL6360360 | 0.69 | ALDH1A1 (0.68) | HPGDALDH1A1L3MBTL1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | HPGD 547/4885ALDH1A1 210/4885L3MBTL1 1464/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | HPGD 547/4885ALDH1A1 210/4885L3MBTL1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.